Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir PK in Healthy Japanese Adults
NCT05905497Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 5 and Area Under the Plasma Concentration-Time Curve at Day 5. Started Apr 2023; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05905497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905497.